These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27222271)

  • 21. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine.
    Jauregizar N; de la Fuente L; Lucero ML; Sologuren A; Leal N; Rodríguez M
    Clin Pharmacokinet; 2009; 48(8):543-54. PubMed ID: 19705924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers.
    Turncliff R; DiPetrillo L; Silverman B; Ehrich E
    Clin Ther; 2015 Feb; 37(2):338-48. PubMed ID: 25456560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects.
    van der Ark PD; Golor G; van Nueten L; Nandy P; de Boer P
    J Psychopharmacol; 2018 Dec; 32(12):1330-1340. PubMed ID: 30182786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
    Khosravan R; Grabowski BA; Wu JT; Joseph-Ridge N; Vernillet L
    Clin Pharmacokinet; 2006; 45(8):821-41. PubMed ID: 16884320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
    Nirogi R; Mudigonda K; Bhyrapuneni G; Muddana NR; Shinde A; Goyal VK; Pandey SK; Mohammed AR; Ravula J; Jetta S; Palacharla VRC
    Clin Drug Investig; 2020 Jul; 40(7):603-615. PubMed ID: 32399853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers.
    Peterschmitt MJ; Burke A; Blankstein L; Smith SE; Puga AC; Kramer WG; Harris JA; Mathews D; Bonate PL
    J Clin Pharmacol; 2011 May; 51(5):695-705. PubMed ID: 20864621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration.
    Muehlan C; Brooks S; Zuiker R; van Gerven J; Dingemanse J
    Eur Neuropsychopharmacol; 2019 Jul; 29(7):847-857. PubMed ID: 31221502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers.
    Darwish M; Hellriegel ET
    Clin Ther; 2011 Jun; 33(6):746-53. PubMed ID: 21704239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability, and pharmacokinetics of oral (S)-oxiracetam in Chinese healthy volunteers: A randomized, double-blind, controlled phase I study.
    Zhang T; Tao Y; Pu J; Zhu M; Wan L; Tang C
    Eur J Pharm Sci; 2024 Jan; 192():106621. PubMed ID: 37898393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3-(1'-Cyclobutylspiro[4H-1,3-benzodioxine-2,4'-piperidine]-6-yl)-5,5-dimethyl-1,4-dihydropyridazin-6-one (CEP-32215), a new wake-promoting histamine H3 antagonist/inverse agonist.
    Hudkins RL; Gruner JA; Raddatz R; Mathiasen JR; Aimone LD; Marino MJ; Bacon ER; Williams M; Ator MA
    Neuropharmacology; 2016 Jul; 106():37-45. PubMed ID: 26400408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
    Zhang M; Ballard ME; Pan L; Roberts S; Faghih R; Cowart M; Esbenshade TA; Fox GB; Decker MW; Hancock AA; Rueter LE
    Brain Res; 2005 May; 1045(1-2):142-9. PubMed ID: 15910772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study.
    Muehlan C; Heuberger J; Juif PE; Croft M; van Gerven J; Dingemanse J
    Clin Pharmacol Ther; 2018 Nov; 104(5):1022-1029. PubMed ID: 29446069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.